Castle Biosciences Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic The company's DecisionDx-SCC is meant to predict risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. People in the News: New Appointments at Berkeley Lights, Castle Bio, IsoPlexis, More Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer Premium The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions. Castle Biosciences Q1 Revenues Up 31 Percent The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent. Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M The sale, part of Myriad's planned strategic refocusing of its business, will allow Castle to bolster its pipeline of tests for dermatologic cancers. Apr 16, 2021 People in the News: New Appointments at ACMG, InterVenn Biosciences, Castle Biosciences, More Mar 8, 2021 Castle Biosciences Q4 Revenues Down 2 Percent Jan 4, 2021 GenomeWeb Index Ends 2020 on Upswing With Pacific Biosciences in Lead Dec 23, 2020 In Brief This Week: Natera, Sync for Genes, Castle Biosciences, BioMérieux, PathogenDx, More Dec 16, 2020 Castle Biosciences Prices $232M Public Offering of Common Stock Dec 3, 2020 Local Coverage Determinations Roundup: Castle Bio Nov 9, 2020 Castle Biosciences Q3 Revenues Up 3 Percent Nov 6, 2020 Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests Oct 22, 2020 Local Coverage Determinations Roundup: CareDx, Castle Bio, Decipher Biosciences Oct 8, 2020 Castle Bio Receives Expanded Medicare Coverage for Melanoma Test Sep 4, 2020 People in the News: New Appointments at Castle Biosciences, Akoya Biosciences, Syapse, More Aug 10, 2020 Castle Biosciences Q2 Revenues Up 18 Percent Jun 25, 2020 Castle Biosciences Prices $74M Public Offering May 11, 2020 Castle Biosciences Doubles Q1 Revenues Apr 3, 2020 People in the News: Kim Popovits, Miles Harrison, Matt Sargent, More Mar 10, 2020 Castle Biosciences Q4 Revenues Increase 54 Percent, Full-Year 2019 Revenues More Than Double Feb 3, 2020 Illumina Stock Drags GenomeWeb Index Down in January Jan 9, 2020 Castle Biosciences Reports Preliminary Q4 Melanoma Test Results Up 37 Percent Jan 2, 2020 Qiagen Stock Tanks in December, Fluidigm Shares Soar as GenomeWeb Index Ends 2019 on High Note Nov 11, 2019 Castle Biosciences Q3 2019 Revenues Quadruple Load More Breaking News Roche Receives FDA EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test Decode Study Identifies Proteomic Predictors of All-Cause Mortality In Brief This Week: Natera, Bruker, Bayer, and More New Products Posted to GenomeWeb: Labcorp, Omniseq, Dovetail Genomics, DNA Script, More People in the News: New Appointments at Sema4, Strata Oncology, Bionano Genomics, More Co-Diagnostics Gets CE Mark for Saliva-Based Molecular SARS-CoV-2 Test The Scan Billions for Antivirals The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports. NFT of the Web Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports. 23andMe on the Nasdaq 23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported. Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.